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Abstract 
The critical functions of dendritic cells (DCs) in immunity and tolerance have been 
demonstrated in many animal models but their non-redundant roles in humans are 
more difficult to probe. Human primary immunodeficiency (PID), resulting from single 
gene mutations, may result in DC deficiency or dysfunction. This relatively recent 
recognition illuminates the in vivo role of human DCs and the pathophysiology of the 
associated clinical syndromes.  In this review, the development and function of DCs as 
established in murine models and human in vitro systems, is discussed.  This forms 
the basis of predicting the effects of DC deficiency in vivo and understanding the 
consequences of specific mutations on DC development and function.  DC deficiency 
syndromes are associated with heterozygous GATA2 mutation, bi-allelic and 
heterozygous IRF8 mutation and heterozygous IKZF1 mutation.  The intricate 
involvement of DCs in the balance between immunity and tolerance is leading to 
increased recognition of their involvement in a number of other immunodeficiency and 
autoimmune conditions. Owing to the precise control of transcription factor gene 
expression by super-enhancer elements, phenotypic anomalies are relatively 
commonly caused by heterozygous mutations. 
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The role of Dendritic cells in Immunity and Tolerance 
Immunity 
As professional antigen presenting cells, the prototypic function of Dendritic Cells 
(DCs) is to activate and prime naïve helper and cytotoxic T cell responses. T cell 
receptor (TCR) recognition of cognate antigen in the context of MHC provides 
specificity. T cell activation is driven by a second co-stimulatory signal generated 
through the binding of CD28 on the T cell with B7 molecules (CD80 and CD86) on the 
DC. Cytokine secretion by DCs provides a third signal, triggering specific STAT 
activation pathways to determine T effector lineage. The specificity of cytokine 
secretion is determined by recognition of pathogen-associated molecular patterns 
(PAMPs) by pattern recognition receptors (PRRs) on DCs, including Toll-like receptors 
(TLRs), NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs), a process also 
resulting in DC activation with up regulation of co-stimulatory and MHC molecules. 
These processes may be spatially separated, as antigen-laden, activated DCs are 
able to migrate from peripheral tissues through lymphatics to secondary lymph organs 
where they interact with T cells. 
DCs have a unique ability to phagocytose and present exogenous antigens to CD8+ T 
cells in the context of MHC Class I, a process termed cross-presentation[1]. Cross-
priming of CD8+ T cells occurs when the DCs are activated by PRR ligation or in the 
presence of T cell help[2], a mechanism important in viral and tumor immunity (Figure 
1). 
 
In addition to their critical role in adaptive immunity, DCs play a non-redundant role in 
innate immunity. Their ability to detect pathogen and elaborate cytokines facilitates the 
activation of innate immune cells including innate lymphoid cells (ILCs)[3], Natural 
Killer (NK) cells[4] and neutrophils[5], to limit the spread of pathogens during the 
initiation of adaptive immune mechanisms (Figure 1).   
Tolerance 
An alternative outcome of DC:T cell interaction is tolerance (reviewed in [6]). Owing to 
continuous steady-state migration of tissue DCs to lymph organs[7], this is likely to be 
the predominant type of encounter in health. In the absence of DC activation, antigen 
presentation or cross-presentation results in the functional inactivation, anergy or 
deletion of CD4 or CD8 T cells, respectively([8],[9]). Ligation of T cell associated co-
inhibitory molecules including CTLA4 or PD-1 by B7 molecules or PD-L1/L2, provides 
additional inhibitory signals[10]. DC secretion of inhibitory cytokines, such as TGF, 
triggers up regulation of T cell Foxp3 and generation of regulatory T cells (Tregs)[11], 
which reciprocally maintain a tolerogenic DC phenotype[12]. Secretion of indoleamine 
2,3-dioxygenase (IDO) by DCs contributes to tolerance by depleting tryptophan and 
causing apoptosis of effector T cells[13]. These mechanisms are important in 
maintaining peripheral tolerance to self-antigens and commensal microbes but also 
play a role in thymic central tolerance[14]. In the thymus, migratory DCs present self-
antigen from the periphery[15] and resident DCs present blood-derived and tissue-
specific antigens from medullary thymic epithelial cells[16], for the elimination of self-
reactive T cells and induction of natural Tregs[17]. 
 
DC subsets 
Similarly to T cells, ‘division of labour’ is provided by the existence of several different 
types of DC. Due to their expression of particular PRRs and secretion of specialized 
cytokines, these subsets respond preferentially to pathogens and differentially polarize 
T cells. This allows a large repertoire of responses to antigenic stimuli in the initiation 
and regulation of immunity and tolerance. Flexibility is also conferred by phenotypic 
and functional plasticity dependent on anatomical location and the microenvironment. 
Plasmacytoid DC (pDC) and two subsets of myeloid or conventional/classical DC 
(cDC) are defined by cross-species gene expression studies and classified in a recent 
consensus study primarily based on ontogeny, with anatomical location and surface 
antigen expression added as further refinement[18] (Figure 2).  
Human pDC express CD123, CD303 and CD304 but are negative for cDC markers 
CD11c and CD33. cDC1 are characterized by high expression of CD141, Clec9A, 
XCR1 and BTLA but lower CD11c, while cDC2 have high levels of CD11c, CD1c, 
CD2, SIRPA and lower CD141. Heterogeneity has recently been shown within the 
cDC2[19] and pDC compartments, with the latter containing CD123+ cDC precursor 
cells[20]. 
 
DC development and function 
Haematopoietic lineage specification, including DC development, is driven by the 
expression of specific transcription factors (TFs). TFs may act in multiple lineages, at 
different stages of differentiation, with additional functional roles in mature cells.  
 
Lineage and stage specific control of expression is governed by master TFs and co-
activators, acting at promoter and enhancer elements. Precise regulation of 
expression may be facilitated by a complex structure of multiple enhancers termed 
‘super-enhancers’ (SE)([21],[22]). In contrast to haplosufficient heterozygous variants, 
single-nucleotide polymorphisms associated with autoimmune diseases in GWAS 
studies are enriched in SE regions[23]. Similarly, gene mutations causing disease 
through haploinsufficiency, compared to autosomal recessive mutations, are enriched 
for SE architecture and more likely to encode transcription factors[24]. TFs with super-
enhancer structure may, therefore, be sensitive to gene dosage effects, which result in 
developmental or functional consequences sufficient to cause disease in the 
haploinsufficient state.  
 
Dendritic cell specification occurs independently of monocyte development in the 
steady state. The existing mouse model, whereby DCs develop sequentially through a 
macrophage-DC progenitor (MDP) and common DC progenitor (CDP), has not been 
supported by recent work in human[25] and is discordant with contemporary models of 
haematopoiesis in which lineage priming is observed early in development([26],[27] 
[28]).  
 
pDC 
Differentiation of pDC requires GATA2, PU.1, IRF8, E2-2 (TCF4), ZEB2 and 
suppression of Id2([29],[30],[31],[32]). pDC are able to respond to viral infection, 
expressing TLR7 and TLR9 to sense single stranded RNA and double-stranded DNA, 
respectively[33]. In response, they produce large quantities of type I interferon, mainly 
IFN, through IRF7 signal transduction[34]. They can also secrete TNF and IL-6 
through NF-B signaling pathways. pDC are able to prime CD4 T cells[35] but are also 
able to induce Tregs through the expression of inducible T cell Costimulator ligand 
(ICOS-L)[36] and IDO[37]. They play a role in humoral immunity through the support of 
B cell functions[38] including B cell activation and proliferation[39], plasma cell 
differentiation([40],[41]), class-switching[42] and immunoglobulin secretion[43] (Figure 
2).  
 
cDC1 
cDC1 lineage specification is dependent on GATA2, PU.1, Id2, BATF3 and high levels 
of IRF8([30],[44],[45],[46]). cDC1 are specialized for defense against viruses, 
intracellular pathogens and tumors, through their enhanced ability to cross-present 
antigen to CD8+ T cells and drive Th1 responses. Antigen cross-presentation is 
enabled by expression of TLR3 and CLEC9A and co-localisation of these PRRs within 
early endosomes. Engagement of TLR3 by viral double stranded RNA triggers type I 
interferon production and antigen cross-presentation[47]. CLEC9A is a necrotic cell 
receptor, which directs cell-associated antigens into the cross-presentation 
pathway[48]. Further specialized defenses against intracellular pathogens include the 
elaboration of IL-12, resulting in Th1 polarization and activation of NK cells to form the 
IL-12/IFNaxis (Figure 2). Expression of XCR1 and secretion of CXCL9/10 allows co-
ordination of XCL1-producing, CXCR3-expressing activated T and NK cell cytotoxic 
responses([49],[50]). They also play a role in tolerance, potentiated by the ability to 
secrete TGF[51] and the expression of BTLA, which engages HVEM on T cells to 
promote CD5 expression and peripheral Treg induction[52].   
  
cDC2 
Similarly to pDC and cDC1, cDC2 require GATA2 and PU.1 for development, but 
lineage specification also requires Zeb2 and IRF4([53],[54],[32]). Heterogeneity has 
been described in the cDC2 population in both mice and humans. Murine 
heterogeneity is influenced by tissue site and TF dependence including KLF4 and 
NOTCH2[55]. Phenotypic and functional heterogeneity in human blood cDC2 has 
been demonstrated by transcriptomics[56] and surface expression of CD5[19], but the 
influence of TFs on development has not been elucidated.  
cDC2 express a large repertoire of TLRs (TLR2, 4, 5, 6, 8), NLRs, RLRs and lectins, 
equipping them to respond to a wide range of pathogens. Consequently, they can 
produce many cytokines, including IFN, IL-23, IL-1, TNF and IL-8. Unlike their murine 
counterparts, they are able to secrete large quantities of IL-12 and can cross-present 
antigen in vitro as efficiently as cDC1, when appropriately activated[57]. cDC2 can 
induce Th1, Th2 or Th17 responses, suggesting functional plasticity in vivo (Figure 2). 
DC Inhibitory Receptor 2+ (DCIR2+) cDC2 have been shown to induce tolerance[58] 
in mice. 
 
Tissue DCs and Langerhans Cells 
In most tissues, populations analogous to blood cDC1 and cDC2 can be 
distinguished([59],[18]), but pDC are frequently only found in inflammation.  In 
lymphoid tissue, cDC migrating from tissues (migratory DCs) can be distinguished 
from blood-derived ‘resident DCs’ by their differential expression of HLA-DR and 
CD11c([60],[61]).   Lymphoid tissue also contains a significant number of pDC, even 
during quiescence. 
 
Langerhans cells, originating in stratified epithelia and expressing a unique profile of 
Langerin, CD1a and EpCAM, provided the first example of migratory DC through the 
identification of phenotypically similar cells in skin-draining lymph nodes[62]. Similarly 
to tissue macrophages and brain microglia, murine LCs are first seeded in tissue by 
primitive erythro-myeloid precursors from the yolk sac[63]. They persist by local self-
renewal in steady-state[64] but influx of bone-marrow derived monocyte[65] and non-
monocyte precursors[66] can be seen following inflammation[67]. LC self-renewal is 
observed in human limb transplant experiments[68] but replacement by donor-derived 
cells is seen following haematopoietic transplantation[69]. Establishment of a LC 
network is dependent on PU.1, RUNX3, Id2[70] and signaling from IL-34, TGF or 
BMP7[71] (reviewed in[72]). The function of LCs is to maintain tolerance to 
commensals but detect and respond to pathogens, features which have been 
demonstrated in murine models and in vitro([73],[74],[75],[76]).  
Predicted effects of DC deficiency 
Murine models of constitutive and inducible DC depletion and lineage-restricted 
transcription factor knockouts have helped delineate the non-redundant functions of 
DCs in vivo; their roles in different immune responses, defense against pathogens and 
in tolerance (reviewed in[77]). Selective pressure has maintained many conserved 
elements of immunity between species[78], although identities of cellular phenotype 
and function are not always maintained at high resolution. 
Simple extrapolation from DC-deficient mice challenged with specific pathogens 
predicts that absolute DC deficiency would lead to complex immunodeficiencies and 
immune dysregulation.  Lack of DCs should cause deficient NK cell and ILC activation 
with defective T cell responses due to weak TCR signaling and loss of co-stimulatory 
support. This in turn should lead to deficient responses to viruses, intracellular 
pathogens and immunosurveillance to cancer. Impairment of tolerogenic mechanisms 
would also be predicted to cause autoimmunity or loss of mucosal immune 
homeostasis.  
 
More subtle effects, or pathogen-specific susceptibity, might be seen in the context of 
depletion or dysfunction of a particular DC subset. For example, disruption of the IL-
12/IFN axis associated with loss of cDCs or monocytes would be predicted to 
compromise immunity to mycobacteria while lack of pDC would adversely affect 
antiviral and respiratory pathogen responses and reduce B cell support for the 
development of robust humoral immunity([79],[80]).   
 
Quantitative DC Immunodeficiencies 
In the context of PID, DCs may be reduced in number, defective in function, or both. 
Two syndromes associated with absolute monocyte and DC deficiency have been 
described; heterozygous GATA2([81],[82]) and bi-allelic IRF8 mutations([83],[84]). A 
more subtle DC deficiency is associated with heterozygous IRF8 mutation[83] and 
IKZF1 haploinsufficiency(Cytlak et al., 2017 in review) (Table 1).  
GATA2 haploinsufficiency 
GATA2 is a member of the GATA-binding transcription factor family and is essential 
for the maintenance of haematopoietic stem cells (HSC). Outside the haematopoietic 
system, GATA2 is expressed in endothelial cells[85] and the central nervous 
system([86],[87]). GATA2 haploinsufficiency results in attrition of HSC and progression 
to myelodysplasia and acute myeloid leukaemia, associated with accumulation of 
additional genetic defects, commonly monosomy 7, trisomy 8, ASXL1 or SETBP1 
mutations. In keeping with the observation that monogenic haploinsufficient diseases 
enrich for transcription factors containing super-enhancer regions[24], GATA2  
possesses a 40kb SE region found at -110kb from the transcription start site. This 
region is also implicated in the pathogenesis inv(3)/t(3:3) AML where its translocation 
to the EVI1 gene results in up regulation of EVI1 but haploinsufficiency of GATA2[88].  
There is a wide range of age and phenotypes at presentation but a high penetrance 
with 90% of carriers showing symptoms by the age of 60yrs. A number of syndromes 
have described these features including familial MDS/AML, Emberger’s (deafness, 
lymphedema and MDS/AML) and MonoMAC (monocytopenia with mycobacterium 
avium complex). Extra-hematopoietic effects may manifest as primary lymphoedema, 
dysmorphia or sensorineural deafness.   
 
Prior to the development of classical MDS/AML, immunodeficiency associated with 
failure of mononuclear cell differentiation, resulting in dendritic cell, monocyte and 
lymphoid deficiency (DCML deficiency) in blood and tissues, is recognized in many 
patients. The failure to replenish lymphocytes from bone marrow results in a 
predominance of memory or terminally differentiated B, T and NK cells in blood. The 
presence of plasma cells in tissues, preserved immunoglobulin levels and memory T 
cells affords ongoing immunity to previously encountered antigens but the ability to 
mount effective adaptive immune responses to novel pathogens is critically impaired. 
Interestingly, tissue macrophages and epidermal Langerhans cells are preserved, in 
keeping with their longevity or independence from bone marrow derived precursors. 
The decline in mononuclear cells can be tracked over decades, during which there is a 
predisposition to autoimmunity (hepatitis, erythema nodosum), pulmonary alveolar 
proteinosis, infections (atypical mycobacteria, herpes virus and fungal pathogens) and 
cancer, particularly HPV/EBV-driven malignancies (Figure 3).  
It remains unclear whether DCML deficiency and impaired immunity is an invariant 
finding or whether MDS/AML can occur de novo, particularly in children. 
 
IRF8 mutation 
IRF8, a member of the interferon regulatory factor family, is a haematopoietic TF, also 
known as interferon consensus sequence binding protein (ICSBP), with important 
roles in development and the function of mature cells of both myeloid and lymphoid 
lineages([89],[90],[91]).  
Two patients are described with bi-allelic IRF8 mutations; homozygous K108E 
mutation[83] and compound heterozygous R291Q and R83C mutations[84]. Both 
presented in infancy with infective symptoms, proliferation of granulocytes and absent 
DCs and monocytes. The infant carrying homozygous K108E mutations received 
neonatal BCG vaccine and presented with BCG-osis. The recently described patient 
with compound heterozygous mutations presented with recurrent respiratory virus 
infections from the age of 7 weeks. Both required HSCT at the age of 4 months or 
4yrs, respectively. 
 
More detailed studies revealed a complex immunodeficiency with phenotypic and 
transcriptomic perturbations in multiple lineages. The failure of T cells to elaborate Th1 
or Th17 cytokines and reduced maturation of NK and CD8+ T cells likely resulted from 
insufficient TCR signaling strength in the absence of DCs. This, combined with 
disruption of the IL-12/IFN circuit, contributed to infection with intracellular pathogens 
including low-virulence mycobacterial, mycoplasma and viral infections. Reduced B 
cell class switching with low IgA levels were in keeping with the supportive role of DCs 
in humoral immunity.  
Lymphoid cell intrinsic effects of IRF8 mutations were seen with reduced frequency 
and complexity of somatic hypermutation in B cells, consistent with the  requirement of 
IRF8 for the germinal center reaction[92]. In the T cell compartment, increased GM-
CSF production may have contributed to the granulocyte hyperplasia, driven by the 
unopposed granulocyte promoting action of C/EBP, normally inhibited by IRF8 in 
bone marrow progenitors.  
In both affected individuals, developmental delay with intracerebral calcification was 
observed in the absence of congenital infection. In mouse, IRF8 is necessary for 
microglial development[93] and/or function([94],[95]) but whether this, dysregulated 
interferon responses or as yet undefined mechanisms are responsible, is unknown 
(Figure 4).  
 
The murine IRF8 locus has a SE structure with different elements active in cDC1 and 
pDC lineages[45], consistent with the requirement for precise control of IRF8 levels to 
determine DC lineage specification[45]. PU.1 dependent IRF8 auto-activation is 
necessary for the development of murine CDPs and Batf3 is required to maintain IRF8 
auto-activation for cDC1 but not pDC differentiation[45]. Haploinsufficiency of genes 
controlled by SEs frequently causes a cellular and clinical phenotype. Heterozygous 
T80A mutations have a modest effect on DC development with apparent preservation 
of cDC1 and pDC, loss of cDC2 and the appearance of CD11c+CD1c- cells[96]. This 
unpredicted pattern may represent allele-specific mechanisms not yet elucidated. 
Additional IRF8 variants localized to the IAD domain (P224L and A201V) result in 
subtle effects on cDC1 and pDC but more pronounced effects on NK cell maturation 
and function[97]. It is highly likely that other IRF8 variants exist with allele-specific 
effects on haematopoiesis and immunity. 
 
IKZF1 Haploinsufficiency 
IKZF1 (IKAROS) is the founding member of the IKAROS family of TFs, a key regulator 
of hematopoiesis and a critical factor in murine lymphocyte and plasmacytoid DC 
development and function[98]. Human IKZF1 haploinsufficiency has recently been 
described as a cause of common variable immunodeficiency with attrition of B cells, 
progressive hypogammaglobulinemia, expanded CD8+ T cells, increased risk of 
bacterial sinopulmonary infections and autoimmunity([99],[100]). pDC deficiency with 
expansion of cDC1 and reduced non-classical monocytes is an additional cellular 
phenotype invariably associated with this mutation[101]. 
IKZF1 is critical for the activity of super-enhancers at genes required for pre-B cell 
receptor signaling and differentiation, working with B cell master regulators including 
EBF1 and PAX5[102]. Targets of IKZF1, identified by CHIP-Seq[103], include ID2, 
suppression of which is necessary for pDC development and BATF3, required for 
cDC1 terminal differentiation. De-repression of these loci due to IKZF1 deficiency is 
consistent with the observed phenotype of absent pDCs but preserved or expanded 
cDC1s. 
pDC deficiency may contribute to the increased risk of bacterial respiratory infection, 
commensurate with the role of pDC in prompt bacterial clearance and limitation of 
inflammation in the lung. Lack of pDC support for B cell function and humoral immunity 
may exacerbate the B cell attrition and progressive hypogammaglobulinemia, despite 
the presence of plasma cells in tissues. Reduction of the tolerogenic influence of pDC 
may permit the development of autoimmunity (Figure 5). 
 
Other disorders associated with pancytopenia 
Other primary immunodeficiencies and secondary bone marrow failure syndromes 
result in dendritic and monocyte deficiency. Mutations in adenylate kinase 2 (AK2), 
causing reticular dysgenesis, result in severe pancytopenia, which includes monocyte, 
dendritic cell and lymphoid lineages([104],[105]). CXCR4 mutations, causing WHIM 
(warts, hypogammaglobulinaemia, infections and myelokathexis), prevent leukocytes 
leaving the bone marrow, resulting in peripheral deficiency of granulocytes, monocytes 
and dendritic cells[106]. The functional contribution of antigen presenting cell 
deficiency to these clinical syndromes has not yet been elucidated.   
 Functional DC deficiencies 
DC dysfunction is present in many immunodeficiency syndromes, either through cell 
intrinsic effects of the mutation or dysregulation of DC interactions with other cells 
(Table 1). 
 
Bare lymphocyte syndrome 
The lack of antigen presentation in MHC Class II deficiency, or ‘bare lymphocyte 
syndrome type II’, caused by mutations in CIITA, RFXANK, RFC5 or RFXAP, results in 
failure of adaptive immunity with deficient CD4+ T cell responses and 
hypogammaglobulinemia with poor specific antibody responses[107]. This SCID-like 
phenotype is characterized by recurrent bacterial, invasive fungal, chronic viral and 
intracellular pathogen infections with a life expectancy less than 10 years in the 
absence of definitive treatment with HSCT[108]. 
 
Wiskott-Aldrich Syndrome 
A migratory dendritic cell defect is caused by mutations of the WAS (Wiskott-Aldrich 
syndrome) gene, encoding for a cytoskeletal protein. An abnormal DC:Tcell immune 
synapse results in impaired T cell and antibody responses leading to recurrent 
bacterial and viral infections and autoimmunity[109]. The reported increase in DC 
cross-presentation and expansion of CD8+ T cells in WASp knockout mice has not 
been observed in humans[110]. 
 
CD40/CD40Ligand deficiency 
Reciprocal expression of CD40 and CD40L facilitates complex cross-talk networks 
between activated DCs, B- and T-cells. Dependent on the environment and DC 
subset, CD40 ligation induces activation and cytokine elaboration, driving T helper cell 
polarization and B cell help. Direct contact with B cells up regulates BAFF and APRIL, 
inducing B cell class switching and immunoglobulin secretion (reviewed in[111]). CD40 
or CD40L deficiency, causes hyper-IgM (HIGM) syndrome types 1 and 3, respectively, 
with aberrant B cell class switching and recurrent bacterial respiratory infections. 
However, unlike other causes of HIGM due to B cell intrinsic mutations, CD40/CD40L 
deficiency results in defective cell mediated immunity and increased susceptibility to 
opportunistic infections (reviewed in[112]). 
 
Pitt-Hopkin’s Syndrome 
E2-2 (TCF4) is necessary for murine pDC development[113]. Haploinsufficiency of 
TCF4 in humans causes Pitt-Hopkin’s Syndrome, characterized by abnormal 
craniofacial and neural development, intellectual disability and epilepsy. This is 
associated with reduced numbers of pDC with defective IFN production[29]. The 
relative preservation of a CD123+CD45RA+CD303low population within the CD123+ 
pDC gate was recently explained by its definition as DC precursor[20]. In contrast to 
IKZF1 haploinsufficiency, no additional myeloid cell or B cell intrinsic defects have 
been described. Although not classified as a primary immunodeficiency, one study 
reported recurrent, commonly sinopulmonary infection in 35% of patients[114].  
 
IRF7 deficiency 
IRF7 is necessary for the expression of type I and type III IFN genes in response to 
virus and is constitutively expressed in pDC[115]. Severe influenza infection and 
failure of IFN type I and III production by leukocytes, including pDCs, was found in a 
patient carrying compound heterozygous mutations in IRF7. Peripheral blood pDC 
numbers were preserved[116].  
 
STAT3 loss and gain of function mutations 
STAT3, a member of the ‘transducer and activator of transcription’ (STAT) TF family, 
is responsible for cytokine signal transduction to regulate cell cycle, proliferation, 
differentiation and apoptosis genes. STAT3 dominant negative mutations cause Hyper 
IgE syndrome (AD-HIES or Job’s syndrome) characterized by facial, dental, skeletal 
and connective tissue abnormalities, eczematous rashes, recurrent skin and 
pulmonary staphylococcal and mycotic infections with cold-abscess formation. 
Defective Th17 responses, due to T cell-intrinsic failure of STAT3 up regulation, are 
implicated in the pathogenesis. STAT3 is necessary for pDC homeostasis in mouse, 
required for Flt3 dependent E2.2 expression[117], but pDC numbers were normal in 
humans with HIES[118]. In contrast, reduction in pDC numbers has been described in 
STAT3 gain of function mutations, characterized by diverse symptoms including 
autoimmunity and lymphoproliferation[119]. Some consequences of aberrant STAT3 
function in DCs may be predicted due to its mediation of Flt3 signaling and signal 
transduction of cytokines involved in often autocrine regulation of DC activation 
including IL-6[120], IL-10[121], IL-12[122], IL-23[123] and IL-27[124]. The regulatory 
role of STAT3 in human and murine DCs was supported by the defective tolerogenic 
responses to IL-10 and increased production of IL-12 seen in STAT3 
deficiency([118],[125]). 
 
DOCK8 Deficiency  
DOCK8 (dedicator of cytokinesis 8) deficiency also causes hyper-IgE syndrome but is 
additionally associated with profound lymphopenia and susceptibility to viral infections. 
Severe pDC deficiency was observed in two patients who successfully cleared 
progressive oral herpes labialis infection when treated with systemic IFN 2[126]. In 
mouse, NLRP10 deficiency is associated with DC migration defects in 
vivo([127],[128],[129]) but this has not been examined in human. 
 
Hermansky-Pudlak syndrome 
Hermansky-Pudlak syndrome is characterized by oculocutaneous albinism, platelet 
dysfunction and a ceroid storage disorder. A number of types are described, with 
phenotypic variation related to the underlying genetic mutation. Type 2 is caused by 
autosomal recessive AP3B1 mutations and encompasses an immunodeficiency 
phenotype with recurrent viral and bacterial infections. AP3B1 encodes for the beta3A 
subunit of AP-3 (adaptor protein 3) complex, involved in cargo-specific transport of 
proteins from endosomes to lysosomes. Defects in cytotoxic T and NK cells have been 
described[130]. Defects have also been shown in CD1-dependent antigen 
presentation[131], TLR7/9 dependent secretion of type I interferon by plasmacytoid 
DCs[132] and delayed maturation and cytokine secretion by monocyte-derived 
DCs[133].  
 
 
The multi-lineage and multi-level influence exerted by transcription factors and the 
‘cross-lineage’ expression of functional molecules suggests that single gene defects 
are likely to affect more than one lineage or immune function. DC, lymphoid and 
myeloid cells all share common origins and the term ‘complex immunodeficiency’ has 
come to denote defects involving multiple immune cells and their functions. 
Syndromes associated with neutropenic states may result from mutations in genes 
also found to be important in murine DC development such as GFI1[134] and 
ELANE[135]. Similarly, genetic mutations implicated in the B- or T- cell dysfunctions of 
combined or variable immunodeficiencies may affect DC function including TLR3[136], 
TRAF3[137], ADA[138] or JAK3[139]. Genes with important roles in DC differentiation 
or function have recently been identified as novel candidate PID-causing genes, based 
on their biological proximity to known causative genes, through analysis of the ‘human 
gene connectome’([140],[141]).  
 
PID provides the opportunity to interrogate the influence of single genes on DC 
differentiation and function and the non-redundant roles of DC in vivo. 
Complementarily, recognition of the involvement of DCs in the pathophysiology of PID 
provides opportunity for novel interventions in these complex syndromes. The central 
role of DCs in tolerance and immunity, predicts that complex immunodeficiency states 
involving DCs will continue to feature significantly among newly discovered PID 
disorders. 
 
  
Figure 1: DC:T cell interactions 
DCs may present endogenous antigen in the context of MHC Class I (MHCI) for 
presentation to CD8+ T cells, or Class II (MHCII) for presentation to CD4+ T cells.  
Endogenous or intracellular pathogen-derived proteins undergo cytosolic proteosomal 
degradation before loading onto MHCI in the endoplasmic reticulum (ER) and 
transport to the surface. Peptides presented in the context of MHC class II are derived 
largely through proteolytic degradation in the endosome. These peptides may be 
derived from exogenous material entering the cell through endocytosis, or endogenous 
proteins internalized in the endosome by autophagy. Alternatively, DCs may cross-
present exogenous antigen in the context of MHCI. Phagocytosis internalizes 
exogenous antigen into the phagosome where it may be degraded and loaded directly 
onto MHCI (vacuolar pathway) or exported to the cytosol for proteosomal degradation 
(cytosolic pathway) and MHCI loading in the ER or re-importation to the phagosome. 
TLR recognition of pathogen associated molecular patterns (PAMPs) induces the 
recruitment of signal transduction complexes, the activation of signaling pathways to 
regulate inflammatory and immune gene sets, elaborate cytokines and up regulate co-
stimulatory molecules. Activation of the DC in this way provides co-stimulatory and 
cytokine driven signals to induce T cell immunity. Recognition of presented antigen by 
the TCR in the absence of co-stimulation or in the presence of co-inhibitory signals 
results in T regulatory cell generation or T cell anergy/apoptosis. 
 
Figure 2: DCs in immunity 
Dendritic cells orchestrate the immune response to pathogens and regulate tolerance. 
Although best known for their initiation of adaptive immunity, they have additional non-
redundant roles in innate immunity. Specialized functions, often conferring pathogen-
specific immunity, may be performed by particular DC subsets, although likely 
developmental and functional plasticity exists. Th1 responses and cytotoxic CD8+ and 
NK cell functions are required for defense against intracellular pathogens and tumor. 
cDC1 claim specialization for antigen cross-presentation and both cDC1 and cDC2 
can elaborate IL-12 to support IFNproduction. Th2 and Th17 responses are more 
commonly associated with cDC2 activation, which may also result in elaboration of 
neutrophil chemotractants or stimulants. Heterogeneity exists within the cDC2 
population which may include cells developmentally relation to monocytes. 
Inflammatory monocyte-derived DCs resemble cDC2s by a number of surface 
markers. pDC are specialized to produce large amounts of anti-viral IFN and 
maintain humoral immunity through support of B cell functions. 
 
 
 
  
Figure 3: GATA2 deficiency 
Heterozygous mutations in GATA2 result in protean clinical syndromes and symptoms. 
In the hematopoietic compartment, there is attrition of dendritic cells, monocytes, B 
and NK cells (DCML deficiency) resulting in a period of immunodeficiency with some 
immunity maintained by the persistence of memory cells and preservation of tissue 
macrophages and Langerhans cells. During this phase, symptoms may include 
autoimmunity (hepatitis, pannicluitis, erythema nodosum), infection with non-
tuberculous mycobacteria (MonoMAC syndrome), sino-pulmonary infections, warts, 
HPV-related neoplasia and pulmonary alveolar proteinosis. There is a high risk of 
MDS/AML (Familial MDS/AML). Alternative hematopoietic presentations include 
apparent de novo AML, CMML, aplastic anaemia, autoimmune cytopenias. Extra-
hematopoietic effects include sensorineural deafness and primary lymphedema 
(Emberger’s Syndrome: primary lymphedema, deafness and MDS). Absence of cell 
represents complete deficiency, faded cells represent reduced numbers; red cell 
outline represents abnormal phenotype or function. 
 
  
Figure 4: Bi-allelic IRF8 deficiency 
The two reported cases carrying bi-allelic IRF8 mutation presented in infancy with 
vaccination-related BCG-osis (homozygous K108E mutation) or severe respiratory 
viral infections (compound heterozygous R291Q and R83C mutations). Proliferation of 
granulocytes but near absence of monocytes and DCs was observed in both patients. 
There was a reduction in CD4+ and CD8+ memory cells and deficient Th1 and Th17 T 
cell responses. There was evidence for reduced somatic hypermutation in peripheral 
blood B cells and low IgA levels. Tissue macrophages and Langerhans cells were 
preserved. Absence of cell represents complete deficiency, faded cells represent 
reduced numbers; red cell outline represents abnormal phenotype or function. 
 
 
  
Figure 5: IKZF1 haploinsufficiency 
IKZF1 (IKAROS) mutation results in a variably penetrant immunodeficiency 
characterized by progressive attrition of B cells, hypogammaglobulinemia, recurrent 
bacterial sinopulmonary infections and autoimmunity. In the DC compartment, pDC 
deficiency but expansion of cDC1 is seen, implicating IKZF1 in the homeostasis of DC 
subset development. Functional DC defects include failure of IFN elaboration from 
pDC and reduced IL-12 production in response to TLR7/8 ligation. Absence of cell 
represents complete deficiency, faded cells represent reduced numbers; large cell 
represents expanded numbers, red cell outline represents abnormal phenotype or 
function. 
 
 
  
Table 1: Summary of DC deficiencies in PID 
Summary of the genetic defects, clinical and cellular phenotypes found in PIDs known 
to encompass DC deficiency or dysfunction. 
 
 
 
Funding 
This work was supported by The Wellcome Trust (VB, UC; award number 
101155/Z/13/Z) and Bright Red (VB, MC).   
Gene Clinical phenotype Cell phenotype DC Phenotype
Mycobacterial and viral infection
Intracerebral calcification and developmental delay
Heterozygous GATA2
Mycobacterial, viral (HPV) infection. Lymphodema, 
deafness, autoimmunity, malignancy, MDS/AML
Denditic cell, monocyte, B and NK lymphoid 
(DCML) deficiency
Complete absence of DC/monocyte but preservation of 
tissue macrophages and LCs
Heterozygous IKZF1
Sino-piulmonary infections, autoimmunity, susceptibility 
to acute lymphoblastic leukemia
Progressive loss of B cells and immunoglobulins, 
expanded CD8+ T cells. 
Deficient plasmacytoid DCs, expanded cDC1. Reduced 
IFNa and IL-12 production
Neonatal fatal septicaemia 
Hypoplasia of lymphoid organs
CXCR4 (WHIM) Warts (HPV), recurrent bacterial infections, carcinomas
B cell lymphopenia (hypogammaglobulinemia), 
Myelokathexis with neutropenia
Reduced numbers of monocytes and DCs
Bare lymphocyte syndrome: MHC Class II deficiency. 
CIITA, RFXANK, RFX5, RFXAP mutations
Failure to thrive, diarrhoea, respiratory tract infections, 
liver/biliary tract disease
Loss of MHC Class II expression on leukocytes
Deficient antigen presentation and failure to mount 
effective CD4+ T cell responses
WASp (Wiskott-Aldrich Syndrome)
Thrombocytopenia, bacterial and viral infections, atopia, 
autoimmunity, IgA nephropathy, lymphoma
Progressive reduction in T cells
Cytoskeletal protein; affects DC migration and DC:T cell 
immune synapse. Impaired T cell and antibody 
responses
TCF4/E2-2 (Pitt-Hopkins Syndrome)
Recurrent infections in 35% of patients. Distinct facial 
features, epilepsy, intellectual disability
Low IgM Impaired pDC IFNα responses in vitro
STAT3 gain of function
Lymphoproliferation, autoimmunity (cytopenias and 
solid organ), infections, short stature
Variable T cell lymphopenia, reduced CD4-CD8-
TCRa/b+ T cells
Reduced plasmacytoid DCs
STAT3 loss of function (Hyper IgE)
Bacterial (S aureus), aspergillus, Pneumocystis jirovecii, 
mucocutaneous candidiasis, facial, dental, skeletal and 
connective tissue abnormalities
Reduced B cells, elevated IgE with decreased 
specific antibodies
Impaired IL-10 responses in DCs
DOCK8 deficiency (Hyper IgE)
Recurrent infections, cutaneous viral and 
staphylococcal infections,atopy,  susceptibility to cancer
Impaired T cell proliferation, Treg deficiency. Low 
CD27+ memory B cells, decreased NK cells
Severe pDC deficiency
Bi-allelic IRF7 Severe influenza infection in childhood No defects reported Impaired IFN types I and III production from pDC 
Hermansky-Pudlak Syndrome type II (AP3B1 mutation) Recurrent viral and bacterial infections
Impaired NK and CD8+ T cell cytotoxicity and 
degranulation
Defects in CD1 antigen presentation and type I 
interferon secretion from plasmacytoid DCs
Dysfunction
CD40/CD40L
Impaired DC signaling cytokine production and cross-
presentation
Defective class switching: IgM+ and IgD+ B cells 
only. Neutropenia
Opportunistic infections. Gastrointestinal and liver/biliary 
tract disease.
Deficiency
Bi-allelic IRF8
Loss of all monocyte and DC subsets. Impaired 
Th1 and Th17. Myeloproliferation.
Complete absence of DCs/monocytes but preservation 
of tissue macrophages and LCs
Pancytopenia
AK2 (Reticular dysgenesis) Global leukocytopenia Global loss of monocytes, DCs and LCs
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